Desktop version

Home arrow Sociology

  • Increase font
  • Decrease font


<<   CONTENTS   >>

Summary

In summary, headaches are a fascinating condition. The key is to make a proper diagnosis which will then lead to effective treatment. The pathogenesis of many headache syndromes is now understood, and this has led to new treatments.

References

  • 1. Headache classification committee ofthe International Headache Society (IHS). The international classification of headache disorders. 3rd edition. Cephalalgia 2018;38(1):1—211. doi: 10.1177/0333102417738202.
  • 2. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;386(9995):743-800.
  • 3. Kelman L.. Migraine pain location: a tertiary care study of 1283 migraineurs. Headache 2005,45(8): 1038-1047.
  • 4. Campbell J.F., Mitch A., Brisebois Hughes N.M.G.. Spatial distribution of head pain as a factor in migraine experience. Headache 1987;27(3):134—137.
  • 5. Lance J.W., Anthony M. Some clinical aspects of migraine. A prospective survey of 500 patients. Arch Neurol 1966; 15(4):356-361.
  • 6. Rasmussen B.K., Jensen R., Olesen J. A population-based analysis of the diagnostic criteria of the international headache society. Cephalalgia 1991 ;11(3): 129—134.
  • 7. Olesen J. Some of the clinical features of the acute migraine attack. An analysis of 750 patients. Headache 1978;18(5):268-271.
  • 8. Russell M.B., Rasmussen B.K., Fenger K., Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia 1996;16(4):239—245.
  • 9. Evans R.W., Seifert T., Kailasam J., Mathew N.T. The use of questions to determine the presence of photophobia and phonophobia during migraine. Headache 2008;48(3):395-397.
  • 10. Bigal M.E., Liberman J.N., Lipton R.B. Age-dependent prevalence and clinical features of migraine. Neurology 2006;67(2):246—251.
  • 11. Kelman L. Migraine changes with age: IMPACT on migraine classification. Headache 2006;46(7): 1161-1171.
  • 12. Lipton R.B., Dodick D., Sadovsky R., et al. A self-administered screener for migraine in primary care: the ID migraine validation study. Neurology 2003;61(3):375—382.
  • 13. Schiirks M., Buring J.E., Kurth T. Agreement of self-reported migraine with ICHD-II criteria in the women's health study. Cephalalgia 2009;29( 10): 1086—1090.
  • 14. Qiu C., Williams M.A.. Aurora S.K., et al. Agreement of self-reported physician diagnosis of migraine with international classification of headache disorders-II migraine diagnostic criteria in a cross-sectional study of pregnant women. BMC Womens Health 2013;13:50.
  • 15. Maniyar F.H., SprengerT., Monteith T, Schankin C., Goadsby P.J. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 2014;137( 1):232—241.
  • 16. Dodick D.W. A phase-by-phase review of migraine pathophysiology. Headache 2018;58(Suppl 1):4—16.
  • 17. Rothrock J.F. Successful treatment of persistent migraine aura with divalproex sodium. Neurology 1997;48(1):261—262.
  • 18. Haan J., Sluis P., Sluis L.H., Ferrari M.D. Acetazolamide treatment for migraine aura status. Neurology 2000:55( 101:1588-1589.
  • 19. Afridi S.K., Giffin N.J., Kaube H., Goadsby P.J. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 2013;80(7):642—647.
  • 20. Rozen T.D. Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology 2000:55(51:732-733.
  • 21. Rozen T.D. Intravenous prochlorperazine with magnesium sulfate can abort a prolonged migrainous aura during pregnancy. Headache 2003;43(8):901-903.
  • 22. Viana M., Afridi S. Migraine with prolonged aura: phenotype and treatment. Naunyn Schmiedebergs Arch Pharmacol 2018:391(1): 1-10.
  • 23. Marmura M.J., Silberstein S.D., Schwedt T.J. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. Headache 2015;55(1):3—20.
  • 24. Loder E., Burch R., Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52(6):930-945.
  • 25. Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache 2016;56(4):808-816.
  • 26. Hepp Z., Rosen N.L., Gillard P.G., et al. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: retrospective analysis of a US-based insurance claims database. Cephalalgia 2016;36(9):862-874.
  • 27. Shirahige L., Melo L., Nogueira F., Rocha S., Monte-Silva K. Efficacy of noninvasive brain stimulation on pain control in migraine patients: a systematic review and meta-analysis. Headache 2016;56(10):1565-1596.
  • 28. Tassorelli C., Grazzi L., de Tommaso M., et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized Presto study. Neurology 2018;91(4):e364-e373.
  • 29. Starling A.J., Tepper S.J., Marmura M.J., et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE study). Cephalalgia 2018:38(6): 1038—1048. doi: 10.1177/333102418762525.
  • 30. Voss T, Lipton R.B., Dodick D.W., et al. A phase lib randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia Int J Headache 2016;36(9):887—898.
  • 31. Dodick D.W. Migraine. Lancet 2018;391(lo1l27): 1315-1330.
  • 32. Silberstein S.D., Dodick D.W., Bigal M.E., et al. Fremanezurnab for the preventive treatment of chronic migraine. N Engl J Med 20l7;377(22):2113-2122.
  • 33. Tepper S., Ashina M., Reuter U., et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16(6):425-434.
  • 34. Ashina M., Dodick D., Goadsby P.J., et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology 2017;89(12):1237—1243.
  • 35. Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics 2018;15(2):291—303.
  • 36. Mazer-Amirshahi M, Dewey K., Mullins P.M., et al. Trends in opioid analgesic use for headaches in us emergency departments. Aw J Emerg Med 2014:32(9): 1068-1073.
  • 37. Davis C.P., Torre PR., Williams C., et al. Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients. Ain J Emerg Med 1995;13(2): 146—150.
  • 38. Carleton S.C., Shesser R.F., Pietrzak M.P.. et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med 1998;32(2): 129-138.
  • 39. Taheraghdam A.A., Amiri H., Shojaan H., et al. Intravenous dexamethasone versus morphine in relieving of acute migraine headache. Pak J Biol Sci 2011; 14( 12):682—687.
  • 40. Friedman B.W., Kapoor A., Friedman M.S., et al. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. Ann Emerg Med 2008;52(6):705-713.
  • 41. Column I., Rothney A., Wright S.C., et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004:62(10): 1695—1700.
  • 42. Tornabene S.V., Deutsch R., Davis D.P., et al. Evaluating the use and timing of opioids for the treatment of migraine headaches in the emergency department. J Emerg Med 2009;36(4):333-337.
  • 43. Harden R.N., Gracely R.H., Carter T, Warner G. The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. Headache 1996;36(6):352—356.
  • 44. Bigal M.E., Bordini C.A., Tepper S.J., Speciali J.G. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 2002;22(5):345—353.
  • 45. Mauskop A., Altura B.T., Cracco R.Q., Altura B.M. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci (Lond) 1995;89(6):633—636.
  • 46. Orr S.L., Aube M., Becker W.J., et al. Canadian headache society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia 2015;35(3):271—284.
  • 47. Friedman B.W., Mulvey L., Esses D., et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med 2011:57(5):475-482.
  • 48. Saadah H.A. Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine. Headache 1992:32(3): 143-146.
  • 49. Silberstein S.D., Young W.B., Mendizabal J.E., et al. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology 2003;60(2):315-321.
  • 50. Swidan S.Z., Lake A.E., III, Saper J.R. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Curr Pain Headache Rep 2005;9(l):65-70.
  • 51. Taggart E., Doran S., Kokotillo A., et al. Ketorolac in the treatment of acute migraine: a systematic review. Headache 2013;53(2):277—287.
  • 52. Colman I., Friedman B.W., Brown M.D., et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008:336(7657): 1359-1361.
  • 53. Shahien R., Saleh S.A., Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand 2011:123(4):257—265.
  • 54. Deutsch S.I., Burket J.A., Rosse R.B. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol 2009;32(6):350-352.
  • 55. Farooq M.U., Majid A., Pysh J.J., Kassab M.Y. Role of intravenous levetiracetam in status migrainosus. J Headache Pain 2007;8(2):143-144.
  • 56. Akpunonu B.E., Mutgi A.B., Federman D.J., et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995;25(4):464-469.
  • 57. Callaham M., Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26(4):168—171.
  • 58. Ashkenazi A., Young W.B. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache 2005;45(4):350-354.
  • 59. Hoffmann J., May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol 2018;17( 1):75—83.
  • 60. May A., Bahra A., Btichel C., Frackowiak R.S., Goadsby P.J. Hypothalamic activation in cluster headache attacks. Lancet 1998;352(9124):275-278.
  • 61. Ekbom K. Treatment of acute cluster headache with sumatriptan. N Eng J Med 1991 ;325(5):322—326.
  • 62. Ekbom K., Krabbe A., Micieli G., et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6mg) (sumatriptan long-term study group). Cephalalgia 1995;15(3):230—236.
  • 63. van Vliet J.A., Bahra A. Martin V. Intranasal sumatriptan is effective in the treatment of acute cluster headache-a double-blind placebo-controlled crossover study. Cephalagia 2001;21(4):267-272.
  • 64. Rozen T.D. High oxygen flow' rates for cluster headache. Neurology 2004;63(3):593.
  • 65. Cohen A.S., Burns B., Goadsby P.J. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA 2009;302(22):2451—2457.
  • 66. Lambru G., Abu Bakar N.. Stahlhut L. et al. Greater occipital nerve blocks in chronic cluster headache: a prospective open-label study. Eur J Neurol 2014 ;21(2):338—343.
  • 67. Gantenbein A.R., Lutz N.J., Riederer F., Sandor P.S. Efficacy and safety of 121 injections of the greater occipital nerve in episodic and chronic cluster headache. Cephalalgia 2012;32(8):630-634.
  • 68. Rozen T.D. High volume anesthetic suboccipital nerve blocks for treatment refractory chronic cluster headache with long term efficacy data: an observational case-series study. Headache 2019;59(1):56—62. doi: 10.1111 /head. 13394.
  • 69. Rozen T.D., Fishman R.S. Demand valve oxygen: a promising new' oxygen delivery system for the acute treatment of cluster headache. Pain Med 2013;14(4):455—459.
  • 70. Petersen A.S., BarloeseM.C., Lund N.L., Jensen R.H. Oxygen therapy for cluster headache: a mask comparison trial. A single-blinded, placebo-controlled, crossover study .Cephalalgia 2017;37(3):214-224.
  • 71. Holle-Lee D., Gaul C. Noninvasive vagus nerve stimulation in the management of cluster headache: clinical evidence and practical experience. TlierAdv Neurol Disord 2016;9(3):230-234.
  • 72. Fontaine D., Santucci S., Lanteri-Minet M.J. Managing cluster headache with sphenopalatine ganglion stimulation: a review'. Pain Res 2018:11:375-381.
  • 73. Rozen T. Clomiphene citrate for treatment refractory chronic cluster headache. Headache 2008;48(2):286-290.
  • 74. Rozen T.D. Clomiphene citrate as a preventive treatment for intractable chronic cluster headache: a second reported case with long-term follow'-up. Headache 2015;55(4):571—574.
  • 75. Nobre M.E., Peres M.F.P., Filho M.P.F., Leal A.J. Clomiphene treatment may be effective in refractory episodic and chronic cluster headache. Arq Neuro Psiquiatr 2017;75(9):620-624.
  • 76. Matharu M.S., Cohen A.S., Frackowiak R.S.J., Goadsby P.J. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 2006;59(3):535-545.
  • 77. Matharu M.S., Cohen A.S., McGonigle D.J., Ward N, Frackowiak RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004;44(8):747-761.
  • 78. Rozen T.D. How effective is melatonin as a preventive treatment for hemicrania continua? A clinic based study. Headache 2015;55(3):430—436.
  • 79. Beams J.L., Kline M.T., Rozen T.D. Treatment of hemicrania continua w'ith radiofrequency ablation and long-term follow'-up. Cephalalgia 2015;35(13): 1208—1213.
  • 80. Rozen T.D. Complete alleviation of treatment refractory primary SUNCT syndrome with clomiphene citrate (A medicinal deep brain hypothalamic modulator). Cephalalgia 2014;34( 12): 1021—1024.
  • 81. Hassan S., Lagrata S., Levy A., Matharu M., Zrinzo L. Microvascular decompression or neuromodulation in patients with SUNCT and trigeminal neurovascular conflict? Cephalalgia 2018;38(2):393—398.
  • 82. Bahra A. Other primary headaches. Ann Indian Acad Neurol 2012;15(Suppl 1 ):S66—S71.
  • 83. Rozen T.D. New daily persistent headache: a clinical perspective. Headache 2011 ;51(4):641—649.
  • 84. Rozen T.D. Triggering events and new' daily persistent headache: age and gender differences and insights on pathogenesis-a clinic-based study. Headache 2016;56(1): 164—173.
 
<<   CONTENTS   >>